Managing the costs of emerging oncology therapies
ESMO as an organisation is not shying away from the current global economic crisis and is conscious of the growing need to address issues of health economics in the field of oncology.
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
ESMO as an organisation is not shying away from the current global economic crisis and is conscious of the growing need to address issues of health economics in the field of oncology.
Results of the phase III SEARCH trial
The European Society for Medical Oncology (ESMO) has awarded its ESMO Designated Centre of Integrated Oncology and Palliative Care accreditation to 16 new oncology centres
Sorafenib became the standard treatment for advanced HCC five years ago after findings from the SHARP trial showed that treatment with this multi-targeted tyrosine kinase inhibitor (TKI) resulted in a 2.8 month improvement in overall survival (OS) compared with placebo. However, since then, results from Phase 3 trials evaluating targeted agents in this setting have been disappointing.
Long awaited results of the EORTC trial compared single agent doxorubicin versus doxorubicin plus ifosfamide
Active hepatitis B virus (HBV) and hepatitis C virus (HCV) are highly prevalent around the world.
Despite continuing advances in medicine and drug development technology, it remains very difficult for new cancer drugs to gain regulatory approval.
Daily Editorial by Erica Martinelli, Associate Editor of the ESMO Congress Daily - Monday October 2nd 2012
At a Presidential Symposium during ESMO 2012 in Vienna, Professor Florian Lordick from the University Clinic Leipzig and the University Cancer Centre (UCCL), Leipzig, Germany, presented data from the open-label randomised, controlled Phase 3 EXPAND trial of cetuximab in combination with capecitabine and cisplatin as first-line treatment for advanced gastric cancer (LBA3). The rationale for this trial came from previous Phase 2 trial data which suggested that cetuximab, an epidermal growth factor receptor (EGFR) antibody, in combination with first-line fluoropyrimidine with irinotecan or platinum compounds shows promising activity.
In the oncology community, it is common knowledge that sarcomas are rare tumours. Indeed, their overall incidence is approximately five per 100,000 people every year, making the feasibility of conducting statistically powered clinical trials a significant challenge. Adding to this is the fact that sarcomas are made up of several different histological types, so conducting a clinical trial in one specific histological type of sarcoma is virtually impossible!
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.